Prana Biotechnology has developed a proprietary library of class-leading chemical compounds. This library is combined with a drug development program to explore novel therapeutics in multiple disease indications. The scientific focus of the company is upon neurological diseases, particularly Alzheimer‘s, Parkinson‘s and Huntington‘s diseases.

Patents 153show all

  • 57
    A61K - Preparations for medical, dental, or toilet purposes
  • 43
    C07D - Heterocyclic compounds
  • 20
    C07C - Acyclic or carbocyclic compounds
  • 13
    G01N - Investigating or analysing materials by determining their chemical or physical properties
  • 11
    C07K - Peptides
  • 4
    C07F - Acyclic, carbocyclic or heterocyclic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur, selenium or tellurium
  • 3
    G16B - Bioinformatics, i.e. information and communication technology [ict] specially adapted for genetic or protein-related data processing in computational molecular biology
  • 3
    Y02A - Technologies for adaptation to climate change

Clinical Trials 6show all

3Phase 12Phase 21N/A

SEC Filings show all


1
D

Contact Information

Level 2 369 Royal Parade
Parkville, QLD VIC 3052
Australia

Overview

Total FundingEmployeesLast Funding DateStatus
$31,400,00011-502019-01-04Ipo

Crunchbase Investment Rounds

DateAmountRoundValuationLead InvestorOther Investors
2019-01-04$31,400,000Post Ipo Equity

SEC Form D Funding Events

DateOfferedSoldType
2004-06-22Unknown Unknown Other (Paper Filing)